BofA maintained LLY at Buy and a price target of $997.0, but said it was reviewing its estimates on the stock.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that from 2021 to 2023, those rates dropped from 41.9% to 40.3%.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 503.77% and ...

Actually, the best way to lose weight, doctors agree, is through healthy diet and physical activity. People always crave the ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Lilly projects $3.5 billion in revenue from Mounjaro and $1.9 billion for Zepbound ... including Lilly’s Zepbound and Novo ...

Shares of Eli Lilly ( NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for ...

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...

The U.S.-listed shares of Novo Nordisk A/S (NVO), which makes rival diabetes and obesity drugs Ozempic and Wegovy ... total includes $3.5 billion in sales of diabetes treatment Mounjaro, which is ...

Big Pharma is hiding a massive secret about so-called miracle weight-loss drugs like Ozempic – they come with a raft of ...

Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...